Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nanobiotix (NBTX) Cash & Current Investments (2018 - 2025)

Nanobiotix has reported Cash & Current Investments over the past 8 years, most recently at $61.4 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 15.53% year-over-year to $61.4 million; the TTM value through Dec 2025 reached $61.4 million, up 15.53%, while the annual FY2025 figure was $61.4 million, 15.53% up from the prior year.
  • Cash & Current Investments for Q4 2025 was $61.4 million at Nanobiotix, up from $32.6 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $143.5 million in Q2 2021 and troughed at $32.6 million in Q2 2025.
  • A 5-year average of $72.6 million and a median of $71.2 million in 2025 define the central range for Cash & Current Investments.
  • Biggest five-year swings in Cash & Current Investments: skyrocketed 91.82% in 2023 and later crashed 59.76% in 2025.
  • Year by year, Cash & Current Investments stood at $96.0 million in 2021, then plummeted by 56.02% to $42.2 million in 2022, then skyrocketed by 91.82% to $81.0 million in 2023, then crashed by 34.38% to $53.1 million in 2024, then rose by 15.53% to $61.4 million in 2025.
  • Business Quant data shows Cash & Current Investments for NBTX at $61.4 million in Q4 2025, $32.6 million in Q2 2025, and $53.1 million in Q4 2024.